Confocal infrared RM imaging of macular diseases

Article

Ability to observe details of deep retinal structures noninvasively and clearly

The RM imaging enables investigators to observe the details of deep retinal structures, noninvasively and clearly, by illuminating the fundus with an infrared laser and collecting the scattered light reflected from the retina and choroid through a semicircular and pericentral aperture by a new confocal technique. This allows for a clearer pseudo three-dimensional image, which is a new method of detecting abnormalities in the macula.1

Some advantages of using the F10 SLO to examine the macula are: non-invasive procedure, short testing time and the entire extent of the macula can be obtained in one image under non-mydriatic conditions.

This report aims to show some macular diseases features in which this imaging method could be helpful.

Drusen

RM imaging has been reported to detect more drusen then conventional color fundus photography.2 The drusen borders, by this imaging method are well highlighted, making them easier to manually segment and grade.

The measurements of drusen number and area obtained by RM were compared with those obtained using standard colour fundus photography. Drusen number grades were found to be significantly higher using the right (AR) and left (AL) lateral apertures in which the laterally scattered light is captured.

The mean drusen number detection with the AR retromode was almost two times greater than for the colour photographs. Small drusen, as well as drusen more distant from the fovea, were more easily visualized with the AR and AL retromodes. The AR retromode would probably be preferred and recommended in further comparative studies; while drusen appear in an elevated convex shape in the AR, in the AL the conformation seems to be inverted.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.